Humanin: what do we know about its effects and research?

Humanin is marketed as a way to live a longer, healthier life. The studies described here do not establish a therapeutic benefit in humans, however. Evidence suggesting cell protection and possible effects on aging comes from laboratory and animal studies. Human studies so far show associations between humanin levels, age and disease; they do not test treatment with humanin.

What is humanin?

Humanin is a naturally occurring peptide—a short chain of amino acids. It contains 24 amino acids. Its genetic instructions lie in mitochondria, the structures that generate energy in cells. Humanin therefore belongs to the family of mitochondrial-derived peptides. Researchers are investigating its role in aging and how it might protect nerve cells. Wellness providers and sellers of “research peptides” already market it for life extension. Humanin is not an approved medicine.

How does it work?

Research focuses mainly on whether and how humanin:

• Protects cells from damage,
• Promotes nerve cell survival,
• Reduces programmed cell death,
• Improves insulin sensitivity [1] and metabolic signaling. Insulin sensitivity describes how well cells respond to insulin.

How humanin levels change over a lifetime is not consistently understood: some studies report declining levels, while others report increases. Lower levels have been measured in certain diseases.

In laboratory and animal studies, humanin protected nerve cells. Studies in worms and mice have also linked it to longer lifespans and a longer period of life in good health, also called healthspan. These preclinical findings come from research conducted before clinical testing in humans. They suggest possible effects and mechanisms but do not establish a benefit in humans.

Is humanin FDA-approved?

No. Under the approval status described here, humanin is not approved as a therapy by the US Food and Drug Administration or any other regulatory authority. It is being investigated in research and sold on a gray market. It does not appear on the FDA lists for compounding, the preparation of customized medicines. Humanin was also not among the peptides reviewed at the FDA compounding advisory committee’s meetings in 2026.

What does the research show?

The work described includes laboratory and animal experiments and observational human studies. What matters is what these study types can answer: a cell experiment can investigate a protective mechanism; an observational study can show whether humanin levels and health characteristics are associated. Neither establishes whether treatment with humanin helps people.

Type of evidence	What it shows
Laboratory studies	Support cells in the brain release humanin. Under laboratory conditions, it can prevent the loss of connections between nerve cells (2).
Animal studies	Studies report effects on lifespan and the period of life spent in good health (3).
Observational human studies	Humanin can be measured in blood. Studies differ on whether levels fall or rise with age. They show associations, not treatment effects.
Human intervention studies	There are no studies of humanin as a therapy. The benefits promised in marketing have therefore not been established in humans.

Frequently asked questions

Is humanin FDA-approved?

No. Humanin is not FDA-approved for any use in humans. As of September 2026, neither a New Drug Application (NDA) nor a Biologics License Application (BLA) had been approved for humanin. Under the US regulatory status described here, there is also no established route for preparing it as a compounded medicine. On that basis, humanin cannot be marketed for human use in the United States.

Is humanin legal in the United States?

Two questions need to be distinguished: humanin is not an approved medicine, but it is also not classified as a controlled substance under US drug law [4]. Under the legal status described here, there is no established route for therapeutic human use.

Online sellers often label humanin products “research use only.” That label is not drug approval and does not, by itself, establish an exemption from FDA regulation. Purchase for personal use is described as a legal gray area. Whether that characterization is accurate is not resolved here; it would not provide a guarantee of safety in any case.

Can a doctor prescribe humanin?

For the United States, the answer under the regulatory status described here is no. Humanin is not FDA-approved. It also has no established classification for compounding under Section 503A or 503B—the preparation of a customized medicine. Under this interpretation, there is no established route to prescribe humanin for treatment or have it prepared by a licensed pharmacy. As of September 2026, no lawful prescribing route is identified here.

How does humanin differ from MOTS-c?

Humanin and MOTS-c are mitochondrial-derived peptides (MDPs). Their genetic instructions are contained in mitochondrial DNA. They differ in amino acid sequence, mechanism and the questions researchers investigate with them.

Humanin contains 24 amino acids. Research focuses on protecting cells, particularly nerve cells, and on the IGF-1/IGFBP-3 signaling axis [5]. This is a pathway involving insulin-like growth factor 1 and its binding protein 3. MOTS-c contains 16 amino acids. Research on it focuses mainly on metabolism: how does it influence glucose regulation, and what role does it play in adaptation to exercise?

Both peptides are being studied in the biology of aging. They are nevertheless pharmacologically distinct compounds with separate bodies of research. Findings for one cannot automatically be applied to the other. Neither has an approved therapeutic use in humans.

What do human data on humanin actually show?

Human data come exclusively from observational studies. They do not provide a consistent picture of how humanin changes with age. Some studies report a decline with age [5]. In contrast, a cohort of 693 people aged 21 to 113 [6] had higher plasma humanin levels in older people. The highest levels were found in people aged 100 and above. A cohort is a group of people studied together.

A later study found lower humanin levels in Alzheimer’s disease [7], but not in type 2 diabetes. Another study described a genetic variant associated with lower circulating humanin levels [8]. That variant was also associated with faster age-related cognitive decline.

These associations help identify possible research questions. They do not show that lower humanin levels cause the changes observed, or that humanin treatment would counteract them.

What is the humanin analogue S14G-humanin (HNG)?

HNG is a synthetically modified version of natural humanin. Glycine replaces serine at position 14. In laboratory tests of nerve cell protection, this variant showed approximately 1,000-fold greater potency [9] than humanin with its natural amino acid sequence. This figure describes potency under those particular laboratory conditions. It does not establish a treatment advantage in humans.

HNG and natural humanin therefore differ in structure and potency. Whether their risks also differ is unknown: neither substance has human safety data.

Did the April 2026 FDA peptide-list change affect humanin?

Under the list status described here, no. In April 2026, the FDA removed a group of peptides from its Category 2 list [10] because nominators had withdrawn their nominations. That was not a determination that the substances were safe.

The source material describes humanin as absent from the FDA category lists 11. List absence alone is not a complete assessment of current compounding rules. Humanin is not among the six peptides in the October 30, 2026 HHS policy, so that policy does not provide enforcement discretion for humanin. It also does not create an FDA-approved humanin formulation. HHS policy Federal Register

Are peptides legal in 2026?

In the United States, the answer depends on the compound and its use. The FDA has approved specific indications for peptides such as bremelanotide 12 and tesamorelin 13. Approval, bulk-list status, controlled-substance classification, and enforcement discretion are different questions. Humanin is not FDA-approved and is not included in the October HHS policy.

The April Category 2 changes did not themselves approve the affected peptides. The October HHS policy is a separate draft, nonbinding statement describing conditional enforcement discretion while final 503A bulk-list rulemaking continues. It covers six specified single-ingredient peptides under identity, route, prescription, manufacturing, testing, labeling, reporting, and other conditions. Humanin is excluded; MOTS-c acetate has a separate, limited scope for subcutaneous or intramuscular preparations, which cannot be transferred to humanin. The policy creates no binding right and does not establish that a particular seller complies. A clinician and pharmacist should check the current requirements for the exact compound and preparation. HHS policy Federal Register

Sources

• Sources: laboratory and animal studies of humanin in synapse protection (Zárate et al., Frontiers in Aging Neuroscience, 2019, DOI: 10.3389/fnagi.2019.00123 2 ) and lifespan/healthspan (Yen et al., Aging, 2020, DOI: 10.18632/aging.103534 3 ), indexed on PubMed. This document is educational, is not medical advice or a health claim, and is not an offer to sell any product. Original reference Original reference